IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2017 financial results will be released after the market closes on Wednesday, November 8, 2017. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s websi
Category: Business
Samenvatting: NovaTears® van Novaliq voor evaporatieve droge ogen wordt gelanceerd in Nieuw-Zeeland en is goedgekeurd in Australië
HEIDELBERG, Duitsland–(BUSINESS WIRE)–Novaliq GmbH, een specialistisch farmaceutisch bedrijf met een revolutionair platform voor medicijntoediening dat slecht oplosbare geneesmiddelen verandert in effectieve oogheelkundige therapieën, heeft vandaag de lancering van NovaTears® in Nieuw-Zeeland en geregistreerde goedkeuring in Australië aangekondigd. Volgens McCarty komt droge ogen bij circa 7,4 procent van de bevolking van Australië en Nieuw-Zeeland voor, wat gelijkstaat aan meer dan 2 miljoen
Zebra Medical Vision要让人人都能容易地取得更加经济实惠的人工智能医疗照护
纽约–(BUSINESS WIRE)–深度学习影像分析的领导企业Zebra Medical Vision发表AI1的解决方案：这是一套新式的工具，以单次扫描只要均一的1美元，让全球医疗照护服务提供者都能享有该公司现有及未来即将推出的各种算法。这是该公司追求为全球人类提供更经济实惠的优质医疗照护所踏出的另一步。Zebra-Med在医学成像的机器学习和深度学习上是先驱领导，该公司正致力于使其商业模式达到前所未见的透明化，以加速全球采用能促进卫生的高级工具。 过去20年来，医疗影像服务的需求愈来愈高，其增长的速度远远超过合格医生增加的速度，让医疗院所和放射科医生经常在工作量大增的情况下还必须想办法维持对病人照护的水平。在预期未来10年内将有20亿人进入中产阶级的情况下，可以想见医疗照护的危机即将来临。只有采用能显著强化放射科医生能力的新技术，这样的危机才可望解除。自动化的影像分析工具，如Zebra-Med的深度学习引擎，就能提供所需的临床和计算能力，让放射科医生能在病人的照护上获得长足的进步。 在运用上百万帧高画质纵向成像扫描下，Zebra-Med开发出能从成像扫描中自动侦测出各种医学
Zebra Medical Vision to Make AI in Healthcare Accessible & Affordable for All
SHEFAYIM, Israel–(BUSINESS WIRE)–#AI–Zebra-Med is announcing AI1: a new suite that offers all its current and future algorithms to healthcare providers globally for $1 USD per scan.
Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
SAN DIEGO–(BUSINESS WIRE)–Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology and metabolic diseases, announced today that the US Food and Drug Administration (FDA) has granted orphan drug desig…
Conjunctivitis Global Clinical Trials Review 2017 – Trial Numbers & Average Enrollment – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Conjunctivitis Global Clinical Trials Review, H1, 2017″ clinical trials has been added to Research and Markets’ offering. The clinical trial report, Conjunctivitis Global Clinical Trials Review, H1, 2017” provides an overv…
Introducing the EyeQue Insight, the World’s Most Accurate, Fully Mobile Visual Acuity Screener for Children and Adults
SAN FRANCISCO–(BUSINESS WIRE)–#seebeyond–EyeQue Insight is the most accurate, convenient and low-cost way to frequently test and track your family’s eyesight anytime, anywhere.
GenSight Biologics nomme Barrett Katz au poste de Directeur Médical
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce la nomination du Dr Barrett Katz au poste de Directeur Médical. Elle sera effective au 1er novembre 2017. Dr Katz remplace Mohamed Genead, qui a démissionné de s
GenSight Biologics Appoints Barrett Katz as Chief Medical Officer
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and dise…
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change diseas…
Bio-Tissue Announces Strategic Agreement with Optima Pharmazeutische GmbH to Distribute its Natural Ocular Cleanser in Germany
MIAMI & MUNICH/HALLBERGMOOS, Germany–(BUSINESS WIRE)–Bio-Tissue, Inc., a business unit of TissueTech, Inc., is pleased to announce a strategic agreement with Optima Pharmazeutische GmbH, a leading distributor of ophthalmic products for the treatment of dry eye, blepharitis and meibomian gland dysfunction (MGD) in Germany and Austria. The agreement supports efforts to bring Bio-Tissue’s natural ocular cleanser formulated with 4-Terpineol, Cliradex®, to the German eye care professionals market.
Global Ophthalmology Devices Market 2017: Analysis By Device Type & Geography – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmology Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017-2025” report has been added to Research and Markets’ of…
Eye Care Leaders Acquires iMedicWare to Launch Fully Integrated Technology Platform for Ophthalmology
CHARLOTTE, N.C.–(BUSINESS WIRE)–#asc–Eye Care Leaders today announced the acquisition of iMedicWare, and has named Arun Kapur, CEO of iMW, to head ECL’s portfolio of technology solutions.
GenSight Biologics présente des résultats de GS010 et GS030 au Congrès 2017 de la European Society of Gene & Cell Therapy
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (Paris: SIGHT), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce plusieurs présentations de résultats au Congrès 2017 de la European Society of Gene and Cell Therapy (ESGCT) à Berlin, Allemagne, du 17 au 20 octobre 2017. GS01
GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris: SIGHT), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced multiple data presentations at the Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, Germany, October 17-20, 2017. GS010 – Leber’s Hereditary Optic Neuropathy (LHON) “
Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals
LEXINGTON, Mass. & NEW YORK, NY–(BUSINESS WIRE)–Inotek Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals
Southern College of Optometry Provides More Than $1.8 Million in Uncompensated Care
MEMPHIS, Tenn.–(BUSINESS WIRE)–#Memphis–Southern College of Optometry provided $1,844,415 in uncompensated optometric care in the 2016-2017 fiscal year, a 183% increase since 2009.
Anthem Blue Cross and Blue Shield in Virginia Expands Reach of $0 Premium Medicare Advantage and Dual-Eligible Plans
RICHMOND, Va.–(BUSINESS WIRE)–Anthem Blue Cross and Blue Shield in Virginia (Anthem) is expanding its $0 premium Medicare Advantage plans with 46 new plans in 34 additional counties for 2018, bringing the total to 75 counties where Anthem will make plans available to Medicare-eligible Virginians. This expansion complements an already robust portfolio of health plans Anthem offers in the state. All of these plans are available for enrollment in this year’s Medicare annual election period (AEP)
Anthem Blue Cross in California Expands Reach of $0 Premium Medicare Advantage and Dual-Eligible Plans
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Anthem Blue Cross (Anthem) is expanding its Medicare Advantage plans with plans in six additional counties – Kings, Madera, Tulare, Merced, Monterey, San Luis Obispo – for 2018, bringing the total to 21 counties where Anthem will make plans available to Medicare-eligible Californians. This expansion complements an already robust portfolio of health plans Anthem offers in the state, giving residents many choices. All of these plans are available for enroll
Amerigroup Offers $0 Premium Medicare Advantage Plans
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Amerigroup is offering its Medicare Advantage plan in five counties – Bernalillo, Sandoval, Santa Fe, Torrance, and Valencia – to Medicare-eligible New Mexicans for 2018. This expansion complements a robust portfolio of health plans Amerigroup offers in the state. All of these plans are available for enrollment in this year’s Medicare annual election period (AEP). The opportunity to enroll in a Medicare plan begins October 15 and continues through December 7.